

CORRECTION

Open Access



Correction to: Updates on cardiovascular outcome trials in diabetes

Oliver Schnell^{1*}, Lars Rydén², Eberhard Standl¹, Antonio Ceriello^{3,4}
and on behalf of the D&CVD EASD Study Group

Correction to: *Cardiovasc Diabetol* (2017) 16:128

<https://doi.org/10.1186/s12933-017-0610-y>

Following publication of the original article [1], the authors submitted a corrected version of Table 4 (see below), as the original version contained a mistake.

The original article has been corrected.

References

1. Leiter LA, et al. Efficacy and safety of saxagliptin in older participants in the SAVOR-TIMI 53 trial. *Diabetes Care*. 2015;38(6):1145–53.
2. Scirica BM, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. *N Engl J Med*. 2013;369(14):1317–26.
3. White WB, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. *N Engl J Med*. 2013;369(14):1327–35.
4. Zannad F, et al. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. *Lancet*. 2015;385(9982):2067–76.
5. Green JB, et al. Effect of sitagliptin on cardiovascular outcomes in Type 2 diabetes. *N Engl J Med*. 2015;373(3):232–42.
6. Pfeffer MA, et al. Lixisenatide in patients with Type 2 diabetes and acute coronary syndrome. *N Engl J Med*. 2015;373(23):2247–57.
7. Zinman B, et al. Empagliflozin, cardiovascular outcomes, and mortality in Type 2 diabetes. *N Engl J Med*. 2015;373(22):2117–28.
8. Marso SP, et al. Liraglutide and cardiovascular outcomes in Type 2 diabetes. *N Engl J Med*. 2016;375(4):311–22.
9. Marso SP, et al. Semaglutide and cardiovascular outcomes in patients with Type 2 diabetes. *N Engl J Med*. 2016;375(19):1834–44.
10. Holman RR, et al. Effects of once-weekly exenatide on cardiovascular outcomes in Type 2 diabetes. *N Engl J Med*. 2017;377(13):1228–39.
11. Marso SP, et al. Efficacy and safety of degludec versus glargine in Type 2 diabetes. *N Engl J Med*. 2017;377(8):723–32.
12. Neal B, et al. Canagliflozin and cardiovascular and renal events in Type 2 diabetes. *N Engl J Med*. 2017;377(7):644–57.
13. Holman RR, et al. Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial. *Lancet Diabetes Endocrinol*. 2017;S2213-8587(17):30309–1.

*Correspondence: oliverschnell@lrz.uni-muenchen.de

¹ Forschergruppe Diabetes e. V., Ingolstaedter Landstraße 1, Neuherberg, 85764 Munich, Germany

Full list of author information is available at the end of the article

Table 4 Comparison of outcome results from terminated CVOTs in comparison to placebo

SAVOR-TIMI53 [1, 2]		EXAMINE [3, 4]		TECOS [5]		ELIXA [6]		EMPA-REG OUTCOME [7]		LEADER [8]	
Class	HR (95% CI) p value	Class	HR (95% CI) p value	Class	HR (95% CI) p value	Class	HR (95% CI) p value	Class	HR (95% CI) p value	Class	HR (95% CI) p value
Cardiovascular endpoints											
Primary composite MACE	1.00 (0.89–1.12) 0.99	CV death, MI, or stroke	0.96 (≤ 1.16) 0.32	CV death, MI, UA, or stroke	0.98 (0.89–1.08) 0.65	CV death, MI, UA, or stroke	1.02 (0.89–1.17) 0.81	CV death, MI, or stroke	0.86 (0.74–0.99) 0.04 ^a	CV death, MI, or stroke	0.87 (0.78–0.97) 0.01
Cardiovascular death	1.03 (0.87–1.22) 0.72	Primary endpoint	0.79 (0.60–1.04) 0.10	Secondary endpoint	1.03 (0.89–1.19) 0.71	Primary endpoint	0.98 (0.78–1.22) 0.85	Primary endpoint	0.62 (0.49–0.77) < 0.001	Primary endpoint	0.78 (0.66–0.93) 0.007
Myocardial infarction	0.95 (0.80–1.12) 0.52	Primary endpoint	1.08 (0.88–1.33) 0.47	Secondary endpoint	0.95 (0.81–1.11) 0.49	Primary endpoint	1.03 (0.87–1.22) 0.71	Primary endpoint	0.87 (0.70–1.09) 0.23	Primary endpoint	0.86 (0.73–1.00) 0.046
Stroke	1.11 (0.88–1.39) 0.38	Primary endpoint	0.91 (0.55–1.50) 0.71	Secondary endpoint	0.97 (0.79–1.19) 0.76	Primary endpoint	1.12 (0.79–1.58) 0.54	Primary endpoint	1.18 (0.89–1.56) 0.26	Primary endpoint	0.86 (0.71–1.06) 0.16
Hospitalization for unstable angina	1.19 (0.89–1.60) 0.24	Secondary endpoint	0.90 (0.60–1.37) 0.632	Secondary endpoint	0.90 (0.70–1.16) 0.42	Primary endpoint	1.11 (0.47–2.62) 0.81	Secondary endpoint	0.99 (0.74–1.34) 0.97	Extended primary endpoint	0.98 (0.76–1.26) 0.87
Hospitalization for heart failure	1.27 (1.07–1.51) 0.007	Extended primary endpoint	1.19 (0.90–1.58) 0.220	Secondary endpoint	1.00 (0.83–1.20) 0.98	Secondary endpoint	0.96 (0.75–1.23) 0.75	Secondary endpoint	0.65 (0.50–0.85) 0.002	Extended primary endpoint	0.87 (0.73–1.05) 0.14
Primary composite MACE	7.3	11.3	9.6	13.4	10.5	13.0					
Event rate (%) active group		Event rate (%) active group		Event rate (%) active group		Event rate (%) active group		Event rate (%) active group		Event rate (%) active group	
No. (%) p value		No. (%) p value		No. (%) p value		No. (%) p value		No. (%) p value		No. (%) p value	
Non-cardiovascular endpoints											
Renal event	5.8 0.04	0.9 0.88	1.4 –	1.6 –	5.2 –	5.7 0.003					
Acute pancreatitis	0.3 0.77	0.4 0.5	0.3 0.07	0.2 –	0.3 ^b –	0.4 0.44					
Hypoglycemia events	15.3 < 0.001	6.7 0.74	2.2 0.33	16.6 0.14	2.8	2.4 0.02					

Table 4 continued

SUSTAIN 6 [9]			EXSCEL [10]			DEVOTE [11]			CANVAS program [12]			ACE [13]		
Class	HR (95% CI) p value	Class	HR (95% CI) p value	Class	HR (95% CI) p value	Class	HR (95% CI) p value	Class	HR (95% CI) p value	Class	HR (95% CI) p value	Class	HR (95% CI) p value	
Cardiovascular endpoints														
Primary composite MACE	0.74 (0.58–0.95) 0.02 ^a	CV death, MI or stroke	0.91 (0.83–1.00) 0.06 ^a	CV death, MI or stroke	0.91 (0.78–1.06) < 0.001	CV death, MI or stroke	0.86 (0.75–0.97) 0.02 ^a	CV death, MI or stroke	0.98 (0.86–1.11) 0.73	CV death, MI, stroke, UA and HF	0.98 (0.86–1.11) 0.73			
Cardiovascular death	0.98 (0.65–1.48) 0.92	Secondary endpoint	0.88 (0.76–1.02)	Primary endpoint	0.96 (0.76–1.21) 0.71	Primary endpoint	0.87 (0.72–1.06)	Secondary endpoint	0.89 (0.71–1.11) 0.29	Secondary endpoint	0.89 (0.71–1.11) 0.29			
Myocardial infarction	0.74 (0.51–1.08) 0.12	Secondary endpoint	0.97 (0.85–1.10)	Primary endpoint	0.85 (0.68–1.06) 0.15	Primary endpoint	0.89 (0.73–1.09)	Secondary endpoint	1.12 (0.87–1.46) 0.38	Secondary endpoint	1.12 (0.87–1.46) 0.38			
Stroke	0.61 (0.38–0.99) 0.04	Secondary endpoint	0.85 (0.70–1.03)	Primary endpoint	0.90 (0.65–1.23) 0.50	Primary endpoint	0.87 (0.69–1.09)	Secondary endpoint	0.97 (0.70–1.33) 0.83	Secondary endpoint	0.97 (0.70–1.33) 0.83			
Hospitalization for unstable primary end-angina	0.82 (0.47–1.44) 0.49	–	–	Primary endpoint	0.95 (0.68–1.31) 0.74	–	–	Secondary endpoint	1.02 (0.82–1.26) 0.87	Secondary endpoint	1.02 (0.82–1.26) 0.87			
Hospitalization for heart failure	1.11 (0.77–1.61) 0.57	Secondary endpoint	0.94 (0.78–1.13)	–	–	Secondary endpoint	0.67 (0.52–0.87)	Secondary endpoint	0.89 (0.63–1.24) 0.48	Secondary endpoint	0.89 (0.63–1.24) 0.48			
Event rate (%) active group														
Primary composite MACE	6.6	11.4	8.5	26.9 ^d	14.4									
No. (%)														
Non-cardiovascular endpoints	–	–	–	–	–									
Renal event	3.9	55 (0.7)	3.8	19.7 ^d	–									
Acute pancreatitis	0.55	26 (0.4)	–	0.32	–									
Hypoglycemia events	22.4 ^c	247 (3.4)	4.9	56.0 ^d	54 (2)									
	–	–	< 0.001 ^a	0.20	0.95									

^a Superiority test

^b Average across all age ranges

^c Severe hypoglycaemia as defined by ADA

^d Number of participants per 1000 patient-years

Author details

¹ Forschergruppe Diabetes e. V., Ingolstaedter Landstraße 1, Neuherberg, 85764 Munich, Germany. ² Cardiology Unit, Department of Medicine K2, Karolinska Institute, 171 76 Stockholm, Sweden. ³ Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) and Centro de Investigación, Biomedica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Barcelona, Spain. ⁴ Department of Cardiovascular and Metabolic Diseases, IRCCS Multimedica Sesto San Giovanni, Via Milanese 300, 20099 Milan, Italy.

The original article can be found online at <https://doi.org/10.1186/s12933-017-0610-y>.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 7 November 2017 Accepted: 7 November 2017

Published online: 15 November 2017

Reference

1. Schnell O, Rydén L, Standl E, Ceriello A, on behalf of the D&CVD EASD Study Group. Updates on cardiovascular outcome trials in diabetes. *Cardiovasc Diabetol*. 2017;16:128. <https://doi.org/10.1186/s12933-017-0610-y>.

Submit your next manuscript to BioMed Central and we will help you at every step:

- We accept pre-submission inquiries
- Our selector tool helps you to find the most relevant journal
- We provide round the clock customer support
- Convenient online submission
- Thorough peer review
- Inclusion in PubMed and all major indexing services
- Maximum visibility for your research

Submit your manuscript at
www.biomedcentral.com/submit

